Adakveo

Active Ingredient(s): Crizanlizumab-tmca
FDA Approved: * November 15, 2019
Pharm Company: * NOVARTIS PHARMS CORP
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Adakveo Overview

Crizanlizumab, (brand name Adakveo), is a monoclonal antibody developed by Novartis targeted towards P-selectin. It was announced by the company as an effective drug to prevent vaso-occlusive crisis in patients with sickle cell anemia. The result of the Phase II SUSTAIN clinical trial was published in December 2016.[2] Crizanlizumab is a treatment to reduce the frequency of vaso-occlusive crisis – a common and painful complication of sickle cell disease that occurs when ...

Read more Adakveo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Crizanlizumab

Recent Adakveo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Adakveo: (1 result)

Sorted by National Drug Code

• 0078-0883 Adakveo 10 mg/ml Intravenous Injection by Novartis Pharmaceuticals Corporation

Other drugs which contain Crizanlizumab-tmca or a similar ingredient: (1 result)

• CRIZANLIZUMAB